Diabetes Therapeutics Global Market Report 2025

Description

Diabetes therapeutics encompasses the range of medical treatments and interventions aimed at managing and controlling diabetes, a condition marked by elevated blood sugar levels resulting from issues with insulin production or utilization. These treatments include medications such as insulin (crucial for type 1 diabetes and sometimes used in type 2), oral drugs like metformin, and newer options such as GLP-1 receptor agonists and SGLT2 inhibitors, which lower blood glucose through different mechanisms.

The primary categories of drugs in diabetes therapeutics include oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs. Oral anti-diabetic drugs are taken by mouth to reduce blood sugar levels in individuals with diabetes. The condition is primarily classified into type 1 and type 2 diabetes. Routes of administration vary and include oral, subcutaneous, and intravenous methods, with distribution occurring through channels such as online pharmacies, hospital pharmacies, and retail pharmacies, addressing applications in both prevention and treatment or care.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The diabetes therapeutics market research report is one of a series of new reports from The Business Research Company that provides diabetes therapeutics market statistics, including diabetes therapeutics industry global market size, regional shares, competitors with a diabetes therapeutics market share, diabetes therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes therapeutics industry. This diabetes therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetes therapeutics market size has grown rapidly in recent years. It will grow from $153.67 billion in 2024 to $170.06 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the early rise in diabetes prevalence, broad adoption of oral hypoglycemic agents, initial use of injectable insulin therapies, increased awareness and education on self-management, and the introduction of biosimilar insulins into the market.

The diabetes therapeutics market size is expected to see rapid growth in the next few years. It will grow to $252.95 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth during the forecast period can be attributed to rising digital literacy, growing adoption of non-insulin injectable drugs, the expansion of digital health platforms, increasing demand for personalized and combination therapies, and enhancements in healthcare infrastructure and access to diabetes care. Key trends anticipated in the forecast period include automated insulin delivery (AID) systems, the use of artificial intelligence (AI) in diabetes management, improved device interoperability, the rise of digital health applications, and the advancement of remote patient monitoring (RPM).

The growing prevalence of obesity is expected to drive the expansion of the diabetes therapeutics market in the coming years. Obesity, characterized by excessive fat accumulation that poses a health risk, is a major contributing factor to type 2 diabetes. This rise in obesity is largely attributed to the increasing consumption of high-calorie diets, including processed and fast foods high in sugar and fat, coupled with declining physical activity, which leads to excessive weight gain. Diabetes therapeutics assist in managing obesity by improving blood sugar control and promoting weight loss through medications such as GLP-1 receptor agonists, which help reduce appetite and slow digestion, thereby enhancing metabolic health in obese individuals. For example, in May 2024, a report by the Office for Health Improvement and Disparities, a UK-based government department, revealed that between 2022 and 2023, approximately 64% of adults aged 18 and older were classified as overweight or living with obesity, up from 63.8% the previous year. As a result, the increasing prevalence of obesity is contributing to the growth of the diabetes therapeutics market.

Key companies in the diabetes therapeutics space are developing innovative approaches, such as cognitive behavioral therapy (CBT), to support personalized diabetes care and improve glycemic control in patients with type 2 diabetes. CBT is a structured, evidence-based psychological treatment that helps individuals recognize and change unhelpful thought patterns and behaviors. For instance, in October 2023, Better Therapeutics Inc., a U.S.-based digital therapeutics company, launched AspyreRx, a digital therapeutic app for diabetes. Approved by the FDA for treating type 2 diabetes, AspyreRx delivers tailored CBT to patients aged 18 and older, promoting behavior changes that enhance diabetes management. Previously known as BT-001, the app showed statistically and clinically significant, sustained reductions in A1c levels compared to standard care, along with improvements in blood pressure, weight, mood, and quality of life in a randomized controlled trial.

In June 2023, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired Sigilon Therapeutics Inc. for $0.034 billion. The acquisition aims to strengthen Eli Lilly's diabetes care portfolio by advancing innovative cell therapies for type 1 diabetes. Specifically, it focuses on the continued development of Sigilon's SIG-002 program, which seeks to restore natural insulin production using encapsulated islet cell replacement. This approach has the potential to provide a functional cure for type 1 diabetes and significantly reduce the daily disease management burden for patients. Sigilon Therapeutics Inc. is a U.S.-based biotechnology company specializing in diabetes therapeutics.

Major players in the diabetes therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Tandem Diabetes Care Inc., Lexicon Pharmaceuticals Inc., Better Therapeutics Inc., Adocia S.A., and Oramed Pharmaceuticals Inc.

North America was the largest region in the diabetes therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetes therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetes therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetes therapeutics market consists of revenues earned by entities by providing services such as blood sugar monitoring, medication management, insulin therapy support, and lifestyle counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes therapeutics market also includes sales of insulin, oral hypoglycemic agents, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetes Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetes therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetes therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetes therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug: Oral Anti-Diabetic Drugs; Insulin; Non-Insulin Injectable Drug; Combination Drug
2) By Type: Diabetes 1; Diabetes 2
3) By Route Of Administration: Oral; Subcutaneous; Intravenous
4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
5) By Application: Preventive; Treatment Or Care
Subsegments:
1) By Oral Anti-Diabetic Drugs: Biguanides; Sulfonylureas; DPP-4 Inhibitors; SGLT-2 Inhibitors; Thiazolidinediones; Meglitinides; Alpha-Glucosidase Inhibitors
2) By Insulin: Rapid-Acting Insulin; Short-Acting Insulin; Intermediate-Acting Insulin; Long-Acting Insulin; Premixed Insulin
3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists; Amylin Analogs
4) By Combination Drug: Oral Combination Therapies; Oral and Injectable Combination Therapies
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck & Co Inc.; Novartis AG; Sanofi S.A.; AstraZeneca PLC; Abbott Laboratories; Medtronic plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Novo Nordisk A/S; Boehringer Ingelheim International GmbH; Biocon Biologics Limited; MannKind Corporation; Tandem Diabetes Care Inc.; Lexicon Pharmaceuticals Inc.; Better Therapeutics Inc.; Adocia S.A.; Oramed Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r36978

1. Executive Summary

2. Diabetes Therapeutics Market Characteristics

3. Diabetes Therapeutics Market Trends And Strategies

4. Diabetes Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Diabetes Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Diabetes Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Diabetes Therapeutics Market Growth Rate Analysis
5.4. Global Diabetes Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Diabetes Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Diabetes Therapeutics Total Addressable Market (TAM)

6. Diabetes Therapeutics Market Segmentation

6.1. Global Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Anti-Diabetic Drugs
Insulin
Non-Insulin Injectable Drug
Combination Drug
6.2. Global Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diabetes 1
Diabetes 2
6.3. Global Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Subcutaneous
Intravenous
6.4. Global Diabetes Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
6.5. Global Diabetes Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preventive
Treatment Or Care
6.6. Global Diabetes Therapeutics Market, Sub-Segmentation Of Oral Anti-Diabetic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biguanides
Sulfonylureas
DPP-4 Inhibitors
SGLT-2 Inhibitors
Thiazolidinediones
Meglitinides
Alpha-Glucosidase Inhibitors
6.7. Global Diabetes Therapeutics Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rapid-Acting Insulin
Short-Acting Insulin
Intermediate-Acting Insulin
Long-Acting Insulin
Premixed Insulin
6.8. Global Diabetes Therapeutics Market, Sub-Segmentation Of Non-Insulin Injectable Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
GLP-1 Receptor Agonists
Amylin Analogs
6.9. Global Diabetes Therapeutics Market, Sub-Segmentation Of Combination Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Combination Therapies
Oral and Injectable Combination Therapies

7. Diabetes Therapeutics Market Regional And Country Analysis

7.1. Global Diabetes Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Diabetes Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetes Therapeutics Market

8.1. Asia-Pacific Diabetes Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetes Therapeutics Market

9.1. China Diabetes Therapeutics Market Overview
9.2. China Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetes Therapeutics Market

10.1. India Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetes Therapeutics Market

11.1. Japan Diabetes Therapeutics Market Overview
11.2. Japan Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetes Therapeutics Market

12.1. Australia Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetes Therapeutics Market

13.1. Indonesia Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetes Therapeutics Market

14.1. South Korea Diabetes Therapeutics Market Overview
14.2. South Korea Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetes Therapeutics Market

15.1. Western Europe Diabetes Therapeutics Market Overview
15.2. Western Europe Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetes Therapeutics Market

16.1. UK Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetes Therapeutics Market

17.1. Germany Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetes Therapeutics Market

18.1. France Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetes Therapeutics Market

19.1. Italy Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetes Therapeutics Market

20.1. Spain Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetes Therapeutics Market

21.1. Eastern Europe Diabetes Therapeutics Market Overview
21.2. Eastern Europe Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetes Therapeutics Market

22.1. Russia Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetes Therapeutics Market

23.1. North America Diabetes Therapeutics Market Overview
23.2. North America Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetes Therapeutics Market

24.1. USA Diabetes Therapeutics Market Overview
24.2. USA Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetes Therapeutics Market

25.1. Canada Diabetes Therapeutics Market Overview
25.2. Canada Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetes Therapeutics Market

26.1. South America Diabetes Therapeutics Market Overview
26.2. South America Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetes Therapeutics Market

27.1. Brazil Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetes Therapeutics Market

28.1. Middle East Diabetes Therapeutics Market Overview
28.2. Middle East Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetes Therapeutics Market

29.1. Africa Diabetes Therapeutics Market Overview
29.2. Africa Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetes Therapeutics Market Competitive Landscape And Company Profiles

30.1. Diabetes Therapeutics Market Competitive Landscape
30.2. Diabetes Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Diabetes Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. AstraZeneca PLC
31.3. Abbott Laboratories
31.4. Medtronic plc
31.5. Takeda Pharmaceutical Company Limited
31.6. Eli Lilly and Company
31.7. Novo Nordisk A/S
31.8. Boehringer Ingelheim International GmbH
31.9. Biocon Biologics Limited
31.10. MannKind Corporation
31.11. Tandem Diabetes Care Inc.
31.12. Lexicon Pharmaceuticals Inc.
31.13. Better Therapeutics Inc.
31.14. Adocia S.A.
31.15. Oramed Pharmaceuticals Inc.

32. Global Diabetes Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetes Therapeutics Market

34. Recent Developments In The Diabetes Therapeutics Market

35. Diabetes Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Diabetes Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Diabetes Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Diabetes Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer